Literature DB >> 2499958

Disappearance of inhibitor to factor VIII in HIV-infected hemophiliacs with progression to AIDS or severe ARC.

M V Ragni1, F A Bontempo, J H Lewis.   

Abstract

The spontaneous disappearance of the inhibitor to factor VIII (FVIII) was observed in two human immunodeficiency virus (HIV)-infected men with hemophilia A. Both men had end-stage HIV infection, one with acquired immune deficiency syndrome (AIDS) and one with severe AIDS-related complex (ARC). Loss of the inhibitor was associated with a fall in T4 helper lymphocytes to less than 100 per mm3 in both patients. Subsequent spontaneous and traumatic hemorrhages were treated successfully with standard doses of FVIII concentrate, resulting in adequate FVIII:C levels and good hemostasis. The mechanism by which the anti-FVIII inhibitor disappears is not known, but it is likely to be related to a quantitative decline in T4 cell number.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2499958     DOI: 10.1046/j.1537-2995.1989.29589284147.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  14 in total

1.  Avidity of human T cell receptor engineered CD4(+) T cells drives T-helper differentiation fate.

Authors:  Patrick Adair; Yong Chan Kim; Kathleen P Pratt; David W Scott
Journal:  Cell Immunol       Date:  2015-10-23       Impact factor: 4.868

2.  Risk factors for inhibitor formation in haemophilia: a prevalent case-control study.

Authors:  M V Ragni; O Ojeifo; J Feng; J Yan; K A Hill; S S Sommer; M N Trucco; D J Brambilla
Journal:  Haemophilia       Date:  2009-06-26       Impact factor: 4.287

3.  CD4+ T-cell epitopes associated with antibody responses after intravenously and subcutaneously applied human FVIII in humanized hemophilic E17 HLA-DRB1*1501 mice.

Authors:  Katharina N Steinitz; Pauline M van Helden; Brigitte Binder; David C Wraith; Sabine Unterthurner; Corinna Hermann; Maria Schuster; Rafi U Ahmad; Markus Weiller; Christian Lubich; Maurus de la Rosa; Hans Peter Schwarz; Birgit M Reipert
Journal:  Blood       Date:  2012-03-06       Impact factor: 22.113

4.  Design of the INHIBIT trial: preventing inhibitors by avoiding 'danger', prolonging half-life and promoting tolerance.

Authors:  Margaret V Ragni; Lynn M Malec
Journal:  Expert Rev Hematol       Date:  2014-11-05       Impact factor: 2.929

5.  Effect of HLA DR epitope de-immunization of Factor VIII in vitro and in vivo.

Authors:  Leonard Moise; Chang Song; William D Martin; Ryan Tassone; Anne S De Groot; David W Scott
Journal:  Clin Immunol       Date:  2011-12-08       Impact factor: 3.969

6.  Antibodies to factor VIII in plasma of patients with hemophilia A and normal subjects.

Authors:  J Batlle; E Gómez; E Rendal; J Torea; E Lourés; M Couselo; P Vila; C Sedano; X Tusell; M Magallón; M Quintana; R González-Boullosa; M F López-Fernández
Journal:  Ann Hematol       Date:  1996-05       Impact factor: 3.673

7.  A role for thrombin in the initiation of the immune response to therapeutic factor VIII.

Authors:  Jonathan Skupsky; Ai-Hong Zhang; Yan Su; David W Scott
Journal:  Blood       Date:  2009-09-30       Impact factor: 22.113

8.  Factor VIII-pulsed dendritic cells reduce anti-factor VIII antibody formation in the hemophilia A mouse model.

Authors:  Margaret V Ragni; Wenhu Wu; Xiaoyan Liang; Ching-Chuan Hsieh; Andrea Cortese-Hassett; Lina Lu
Journal:  Exp Hematol       Date:  2009-06       Impact factor: 3.084

Review 9.  From IgG Fusion Proteins to Engineered-Specific Human Regulatory T Cells: A Life of Tolerance.

Authors:  David W Scott
Journal:  Front Immunol       Date:  2017-11-13       Impact factor: 7.561

Review 10.  Human Tregs Made Antigen Specific by Gene Modification: The Power to Treat Autoimmunity and Antidrug Antibodies with Precision.

Authors:  Patrick R Adair; Yong Chan Kim; Ai-Hong Zhang; Jeongheon Yoon; David W Scott
Journal:  Front Immunol       Date:  2017-09-21       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.